Autopsy report · NCT01020305

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

“Decision by funding sponsor due to poor accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Sandy Srinivas

Sponsor type

University, hospital or other

Conditions

Prostate Cancer; Prostatic Neoplasms; Castrate-resistant Prostate Cancer (CRPC); Androgen-insensitive Prostate Cancer; Hormone-refractory Prostate Cancer; Metastatic Disease

Interventions

Temsirolimus; Casodex (bicalutamide)

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
  “Sponsor decision due to low accrual” (87% match in meaning)
• A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
  “Sponsor decision - funding issues” (82% match in meaning)
• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  “Low Accrual, Funding” (78% match in meaning)
• The Effect of Theraworx Foam in Carpal Tunnel Syndrome
  “Lack of Funding from Sponsor” (77% match in meaning)
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
  “funding issues and poor accrual” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.